Get the Stockscreener App
348.29
0.69%
2.3698
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $348.29, with a volume of 807.02K.
It is up +0.69% in the last 24 hours and down -0.42% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$345.92
Open:
$345.515
24h Volume:
807.02K
Relative Volume:
0.30
Market Cap:
$187.76B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.47
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-0.31%
1M Performance:
-0.42%
6M Performance:
+18.91%
1Y Performance:
+25.33%
1-Day Range:
$345.50
$350.67
1-Week Range:
$340.06
$356.90
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
348.30 | 185.90B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
913.59 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.47 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
200.88 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
193.10 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
114.18 | 278.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Lowers Stock Position in Amgen Inc. $AMGN - MarketBeat
David Reese retirement prompts organizational changes at Amgen - The Pharma Letter
Amgen Inc. $AMGN Shares Sold by M&T Bank Corp - MarketBeat
Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings - Insider Monkey
Amgen (AMGN) to Release Earnings on Thursday - MarketBeat
Boston Trust Walden Corp Has $23.54 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Stock Acquired Rep. Maria Elvira Salazar - MarketBeat
The Bull Case For Amgen (AMGN) Could Change Following Strong Q4 Beat And Upbeat 2026 Guidance - simplywall.st
Amgen (NASDAQ: AMGN) CTO David Reese to retire as company realigns AI and R&D - Stock Titan
Maria Elvira Salazar makes significant purchases in Amgen, Boeing, and Cisco By Investing.com - Investing.com South Africa
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER - marketscreener.com
Maria Elvira Salazar makes significant purchases in Amgen, Boeing, and Cisco - Investing.com Canada
AMGN Amgen tops Q4 2025 earnings expectations, posts near 10 percent revenue growth, shares dip 1 percent.Acquisition - Cổng thông tin điện tử tỉnh Lào Cai
Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $221K In Amgen Stock - Benzinga
Amgen Inc. $AMGN Shares Bought by KLP Kapitalforvaltning AS - MarketBeat
Is Amgen Stock Poised For A Rally? - Trefis
Amgen Inc. (AMGN)Pre-Earnings Analysis Ahead of Fiscal Q1 2026 Results ReleasePerformance Review - Cổng thông tin điện tử tỉnh Lào Cai
Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge - Law360
Amgen Named Among America’s Most Innovative Companies in 2026 - Amgen
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know - The Motley Fool
AMGN Initiated Coverage by Canaccord Genuity -- Rating Set to Ho - GuruFocus
Ex-Amgen Worker Files Suit Over Health Plan Tobacco Use Penalty - Bloomberg Law News
Ticino Wealth Invests $2.54 Million in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Novem Group Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Jones Kertz & Associates Inc. Purchases Shares of 14,070 Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stake Decreased by PFG Advisors - MarketBeat
Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside? - AD HOC NEWS
Greystone Financial Group LLC Has $14.69 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation - MSN
Biologics Market: Share and Outlook Driven by Roche, Amgen, and AbbVie Leading Advanced Therapeutics - openPR.com
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to unlock new upside? - AD HOC NEWS
What to Expect From Amgen's Next Quarterly Earnings Report - Barchart.com
Is Amgen (AMGN) stock near a pivot level (Modest Decline) 2026-04-20Institutional Grade Stocks - UBND thành phố Hải Phòng
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive new upside? - AD HOC NEWS
Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) Investor Outlook: Examining the Healthcare Giant’s 106% ROE and Analyst Ratings - DirectorsTalk Interviews
Pfizer (PFE) and Amgen (AMGN) Expand Presence in Hong Kong - GuruFocus
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (PFE:NYSE) - Seeking Alpha
Amgen Inc. Trade Ideas — LSE:0R0T - TradingView
Amgen Inc. stock (US0311621009): Is obesity drug momentum strong enough to drive sustained upside? - AD HOC NEWS
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy - Insider Monkey
Wealth Enhancement Trust Services Inc. Takes $1.58 Million Position in Amgen Inc. $AMGN - MarketBeat
Is It Time To Reconsider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Oak Harvest Investment Services Reduces Stake in Amgen Inc. $AMGN - MarketBeat
GF Fund Management CO. LTD. Acquires 6,216 Shares of Amgen Inc. $AMGN - MarketBeat
Asset Management One Co. Ltd. Has $114.31 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Laps the Stock Market: Here's Why - Yahoo Finance Singapore
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
2.09%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):